Purdue Research Foundation

Endocyte, Inc.

University of Utah Research Foundation

Seattle Children's Hospital

The Government of the United States of America As Represented by the Secretary of the Deptartment of Health and Human Services

On Target Laboratories, LLC

Philip Stewart Low

Sumith A Kularatne

Christopher Paul Leamon

Cagri Abdullah Savran

Yingjuan June Lu

Haiyan Chu

Iontcho Radoslavov Vlahov

Chun-Li Chang

Jyoti Roy

Sakkarapalayam M Mahalingam

Venkatesh Chelvam

Peter F Heinstein

Youngsoon Kim

Mark A Horn

Leroy W Wheeler, Ii

Michael D Kennedy

Yong Gu Lee

Stewart Andrew Low

Dimiter Stanchev Dimitrov

Michael C Jensen

Jindrich Henry Kopecek

Yang Feng

James Matthaei

Jiayin Shen

Wanfeng Huang

Christopher Galliford

Mary Jo Turk

Derek Doorneweerd

Charity Wayua

Wei He

Jiyan Yang

Pravin Gagare

Dor Ben-Amotz

Jeffery Jay Howard Nielsen

Karim N Jallad

Walter Anthony Henne, Jr

Walter A Henne

Suraj U Hettiarachchi

Yen-Hsing Li

Lindsay E Kelderhouse

David H Thompson

Bindu Varghese

Alexander Wei

Ji-xin Cheng

Ronald George Reifenberger

Garth L Parham

Ghanashyam S Acharya

Ananda Kumar Kanduluru

Carrie H Myers

Yeong E Kim

Julie Ruggieri Park

Mohammad Noshi

Madduri Srinivasarao

Stewart A Low

Fenghua Zhang

John Victor Napoleon

Richard Messmann

Boning Zhang

Pengcheng Lu

Navin Robert Charles Pinto

Qingshou Chen

Sumith K Kularatne

Spencer Gardeen

Isaac J Marks

Emanuela Ionela Sega

Ryan Rothenbuhler

Alexei Leonov

Rajesh Kumar Pandey

Rajendra P Bandari

Kulbhushan Durugkar

David Lyvers

Avijit Kumar Adak

David Brownholland

Chung-Li Chang

Balasubramanian Vaitilingam

Andrew R Hilgenbrink

Scott Poh

Compounds, pharmaceutical compositions and methods are provided for reprogramming M2-like macrophages to M1-like macrophages, which reverses the antifibrotic to profibrotic shift observed during the course of fibrotic diseases and certain cancers. The compounds comprise an immune modulator that targets a pattern recognition receptor of a cell and are specific to the cells of interest through the incorporation of a targeting moiety (e.g., folate or a functional fragment or analog thereof). Releasable and/or non-releasable linkers can be included and engineered to facilitate the optimal delivery of the immune modulator. The compounds and compositions can be employed in one or more methods of treatment for fibrotic diseases and/or cancers.

Compounds and methods for the treatment and prevention of fibrotic disease states and cancer

The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for imaging cancer-associated fibroblasts (CAFs) in the tumor microenvironment of a patient. The present teachings relate generally to method of making conjugates comprising a fibroblast activation protein (FAP) inhibitor.

Fibroblast activation protein (FAP)-targeted imaging and therapy

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

Targeted ligand-payload based drug delivery for cell therapy

The targeted delivery of growth factors, vasoactive peptides and other representative anabolic peptide drugs from different signaling cascades to bone fracture for accelerated healing is disclosed herein.

Targeting anabolic drugs for accelerated fracture repair

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

Methods of use for CAR T cells

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

Sequencing method for CAR T cell therapy

Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.

Compounds for positron emission tomography

Cytotoxic lymphocytes expressing chimeric antigen receptors (CAR) that target and bind small conjugate molecules (SCM) are disclosed, as well as methods of using the cells and the SCMs in the treatment of cancer.

Chimeric antigen receptor-expressing T cells as anti-cancer therapeutics

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

Methods and compositions for car T cell therapy

The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds. The disclosure also relates to compositions for incorporating the compounds as used for the targeted imaging of tumors. Conjugation of the amino acid linking groups increase specificity and detection of the compound. Methods and compositions for use thereof in diagnostic imaging are contemplated.

Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors

Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical compositions containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

PSMA binding ligand-linker conjugates and methods for using

The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for incorporating the compounds as used for the targeted imaging of tumors. Conjugation of the amino acid linking groups increase specificity and detection of the compound. Methods and compositions for use thereof in diagnostic imaging are contemplated.

Synthesis and composition of non-amino acid linking groups conjugated to compounds used for the targeted imaging of tumors

The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in SPECT imaging methods.

Carbonic anhydrase IX targeting agents and methods

Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF), it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contractile fibroblasts) that are key for the development of IPF with drugs conjugated with fibroblast activation protein (FAP), this technology helps minimize the production of extracellular matrix in the lungs and provides a new treatment option for patients diagnosed with IPF.

Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis

The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for treating LHRH-R expressing cancer in a patient. The present teachings relate generally to method of making conjugates comprising an LHRH-R antagonist.

Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof

Growing community of inventors

West Lafayette, IN, United States of America

Philip Stewart Low